ABSTRACT
Lung cancer remains the leading cause of cancer-related death worldwide. Most non-small-cell lung cancer patients are diagnosed at advanced stages, when chemotherapy is generally considered palliative treatment. Molecular expression profiling of the tumor as a powerful prognostic tool to predict long-term outcomes in many cancers, including breast, colon, and liver cancer. Biomarkers offer an innovative opportunity to obtain more information about each patient and classified as prognostic, predictive, or pharmacodynamic biomarkers, depending on their potential use. Cisplatin, a platinum-based chemotherapeutic drug, has been used for over 30 years in a wide variety of cancers with varying degrees of success. Taxanes agents are diterpenes produced by the plants of the genus Taxus, and include paclitaxel and docetaxel. Personalized treatment of lung cancer, although quite common in daily clinical practice in some parts of the world, is not widespread in others. Cancer treatments are extremely costly with a lengthy design and testing process with poor safety and bioavailability and often limited efficacy.
